Hermel M, Tsai S, Dlouhy L, B KA, Rana JS, Dani SS, et al. Highlights of cardiovascular disease prevention studies presented at the 2022 American College of Cardiology scientific sessions. Curr Atheroscler Rep. 2022;24(8):671–80.

Article  Google Scholar 

Hermel M, Pelter M, Jordan T, Latif A, Gad MM, Slipczuk L, et al. Highlights of cardiovascular disease prevention studies presented at the 2022 European Society of Cardiology Congress. Curr Atheroscler Rep. 2022:1–13.

Lee MT, George J, Shahab H, Hermel M, Rana JS, Virani SS. Highlights of cardiovascular disease studies presented at the 2021 American Heart Association scientific sessions. Curr Atheroscler Rep. 2022;24(1):61–72.

Article  Google Scholar 

• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005;366(9500):1849–61. Laid the groundwork and provides context for the studies reviewed here.

• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. Laid the groundwork and provides context for the studies reviewed here.

• Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–80. Laid the groundwork and provides context for the studies reviewed here.

• Virani Salim S, Morris Pamela B, Agarwala A, Ballantyne Christie M, Birtcher Kim K, Kris-Etherton Penny M, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia. J Am Coll Cardiol. 2021;78(9):960–93. Laid the groundwork and provides context for the studies reviewed here.

Hussain A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD risk reduction: recent insights and future directions. Curr Atheroscler Rep. 2020;22(7):25.

Article  Google Scholar 

Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, et al. Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease. J Am Coll Cardiol. 2018;72(2):156–69.

Article  Google Scholar 

Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–84.

Article  Google Scholar 

•• Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022. Study presented at AHA 2022 and simultaneously published.

•• Virani SS. The fibrates story - a tepid end to a PROMINENT drug. N Engl J Med. 2022;387(21):1991–2. Study presented at AHA 2022 and simultaneously published.

Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369(9567):1090–8.

Article  Google Scholar 

Virani SS, Nambi V, Ballantyne CM. Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e7–8.

Article  Google Scholar 

Jia X, Gao F, Pickett JK, Al Rifai M, Birnbaum Y, Nambi V, et al. Association between omega-3 fatty acid treatment and atrial fibrillation in cardiovascular outcome trials: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2021;35(4):793–800.

Article  Google Scholar 

•• Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, et al. Comparative effects of low-dose rosuvastatin, placebo and dietary supplements on lipids and inflammatory biomarkers. J Am Coll Cardiol. Study presented at AHA 2022 and simultaneously published.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.

Article  Google Scholar 

• O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109–19. Laid the groundwork and provides context for the studies reviewed here.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.

Article  Google Scholar 

Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. Jama. 2011;305(24):2556–64.

Article  Google Scholar 

• Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e143. Laid the groundwork and provides context for the studies reviewed here.

Virani SS, Ballantyne CM, Petersen LA. Guideline-concordant statin therapy use in secondary prevention: should the medical community wait for divine intervention? J Am Coll Cardiol. 2022;79(18):1814–7.

Article  Google Scholar 

Minhas AMK, Ijaz SH, Javed N, Sheikh AB, Jain V, Michos ED, et al. National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: insights from National Ambulatory Medical Care Survey. Am Heart J. 2022;252:60–9.

Article  Google Scholar 

Chobufo MD, Regner SR, Zeb I, Lacoste JL, Virani SS, Balla S. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020. Eur J Prev Cardiol. 2022;29(14):1830–8.

Article  Google Scholar 

Dixon DL, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, et al. Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J Am Coll Cardiol. 2019;74(13):1728–31.

Article  Google Scholar 

Budoff MJ, Lutz SM, Kinney GL, Young KA, Hokanson JE, Barr RG, et al. Coronary artery calcium on noncontrast thoracic computerized tomography scans and all-cause mortality. Circulation. 2018;138(21):2437–8.

Article  Google Scholar 

Sandhu AT, Rodriguez F, Ngo S, Patel BN, Mastrodicasa D, Eng D, et al. Incidental coronary artery calcium: opportunistic screening of prior non-gated chest CTs to improve statin rates (NOTIFY-1 Project). Circulation. 2022. https://doi.org/10.1161/CIRCULATIONAHA.122.062746.

Eng D, Chute C, Khandwala N, Rajpurkar P, Long J, Shleifer S, et al. Automated coronary calcium scoring using deep learning with multicenter external validation. npj Digital Medicine. 2021;4(1):–88.

Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549–58.

Article  Google Scholar 

Li W, Gu H, Teo KK, Bo J, Wang Y, Yang J, et al. Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47 000 people from China. J Hypertens. 2016;34(1):39–46.

Article  Google Scholar 

Mills KT, Obst KM, Shen W, Molina S, Zhang HJ, He H, et al. Comparative effectiveness of implementation strategies for blood pressure control in hypertensive patients: a systematic review and meta-analysis. Ann Intern Med. 2018;168(2):110–20.

Article  Google Scholar 

Sun Y, Li Z, Guo X, Zhou Y, Ouyang N, Xing L, et al. Rationale and design of a cluster randomized trial of a village doctor-led intervention on hypertension control in China. Am J Hypertens. 2021;34(8):831–9.

Article  Google Scholar 

• Sun Y, Mu J, Wang DW, Ouyang N, Xing L, Guo X, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. The Lancet. 2022;399(10339):1964–75. Laid the groundwork and provides context for the studies reviewed here.

• Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043–52. Laid the groundwork and provides context for the studies reviewed here.